1. Metastatic Cancer of the Prostate Managed with Buserelin Versus Buserelin Plus Cyproterone Acetate
- Author
-
Schroeder, Fritz H., Lock, Tycho M.T.W., Chadha, Dev R., Debruyne, Frans M.J., Karthaus, Herbert F.M., de Jong, Frank H., Klijn, Jan G.M., Matroos, Ans W., and de Voogt, Herman J.
- Abstract
We recruited 71 previously untreated patients with metastatic prostatic carcinoma to 2 separate consecutive prospective phase 2 studies done by the same group of investigators according to the same protocols in which only the treatment regimens differed. Of the patients 58 were treated with the luteinizing hormone-releasing hormone analogue buserelin alone (0.4mg. 3 times daily intranasally) and 13 were treated with buserelin combined with cyproterone acetate, a potent antiandrogen (50mg. 3 times daily orally). The objective of the study was to investigate the efficacy, safety and tolerability of the medication used during at least 12 months by studying adequate endocrine parameters, the rate and duration of response, as well as the rate of progression and possible side effects. All endocrine parameters were studied in 1 laboratory. Modified response criteria of the National Prostatic Cancer Project were used.
- Published
- 1987
- Full Text
- View/download PDF